Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life
Paz Fernández‐Ortega(Institut Català d'Oncologia), Antonio Llombart‐Cussac(Universidad Cardenal Herrera CEU), P. Zabaleta(Onkologikoa), J. San Francisco(Biogipuzkoa Health Research Institute), E. Chirveches(Hospital Universitari de Vic), G Nocea(MSD (Spain)), Cristina Suárez(Complejo Hospitalario de Salamanca), Eric P. Zorrilla(Hospital General Universitario De Valencia), M.T. Caloto(MSD (Spain)), Ana R. Quesada(Hospital Universitari de Girona Doctor Josep Trueta), J. Gómez(Hospital General Universitario de Alicante Doctor Balmis), R. Marquilles(Hospital Universitari Arnau de Vilanova)
Cited by 175
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
|Annals of Oncology|2001|714
Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial
|Journal of Clinical Oncology|2008|464
Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
|Journal of Clinical Oncology|2008|422